Which has stronger earnings and valuation, TECX or EQ?

Equillium is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A Equillium N/A N/A -$22.40M -$0.32 N/A

Is TECX or EQ more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% Equillium N/A -61.43% -53.72%

Does the media prefer TECX or EQ?

In the previous week, Equillium had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Equillium and 3 mentions for Tectonic Therapeutic. Equillium's average media sentiment score of 1.34 beat Tectonic Therapeutic's score of 0.19 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ALLO or EQ?

Equillium is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A Equillium N/A N/A -$22.40M -$0.32 N/A

Is ALLO or EQ more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Equillium N/A -61.43% -53.72%

Does the media refer more to ALLO or EQ?

In the previous week, Equillium had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for Equillium and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.56 beat Equillium's score of 1.34 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Equillium 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, EQ or CRMD?

CorMedix has higher revenue and earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium N/A N/A -$22.40M -$0.32 N/A CorMedix $311.71M 1.98 $163.05M $2.13 3.69

Is EQ or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to Equillium's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% CorMedix 45.25% 45.57% 24.76%

Does the media favor EQ or CRMD?

In the previous week, Equillium had 3 more articles in the media than CorMedix. MarketBeat recorded 6 mentions for Equillium and 3 mentions for CorMedix. Equillium's average media sentiment score of 1.34 beat CorMedix's score of 1.07 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EQ or CTMX?

In the previous week, Equillium had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Equillium and 4 mentions for CytomX Therapeutics. Equillium's average media sentiment score of 1.34 beat CytomX Therapeutics' score of 1.23 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EQ or NGNE more profitable?

Neurogene's return on equity of -37.88% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Neurogene N/A -37.88% -34.70%

Equillium (EQ) Competitors

$2.49 -0.20 (-7.43%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.50 +0.00 (+0.20%)

As of 07/24/2026 07:34 PM Eastern

Compare

EQ vs. TECX, ALLO, CRMD, CTMX, and NGNE

Should you buy Equillium stock or one of its competitors? MarketBeat compares Equillium with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Equillium include Tectonic Therapeutic (TECX), Allogene Therapeutics (ALLO), CorMedix (CRMD), CytomX Therapeutics (CTMX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry.

How does Equillium compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Tectonic Therapeutic's return on equity of -32.33% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Equillium	N/A	-61.43%	-53.72%

Tectonic Therapeutic has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Tectonic Therapeutic currently has a consensus price target of $79.40, indicating a potential upside of 161.44%. Equillium has a consensus price target of $7.57, indicating a potential upside of 204.07%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.82

Equillium is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Equillium	N/A	N/A	-$22.40M	-$0.32	N/A

In the previous week, Equillium had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Equillium and 3 mentions for Tectonic Therapeutic. Equillium's average media sentiment score of 1.34 beat Tectonic Therapeutic's score of 0.19 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Equillium beats Tectonic Therapeutic on 7 of the 13 factors compared between the two stocks.

How does Equillium compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Allogene Therapeutics' return on equity of -56.45% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Equillium	N/A	-61.43%	-53.72%

Allogene Therapeutics currently has a consensus target price of $8.52, indicating a potential upside of 389.78%. Equillium has a consensus target price of $7.57, indicating a potential upside of 204.07%. Given Allogene Therapeutics' higher probable upside, research analysts clearly believe Allogene Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Equillium had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for Equillium and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.56 beat Equillium's score of 1.34 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Equillium has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Equillium is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A
Equillium	N/A	N/A	-$22.40M	-$0.32	N/A

Summary

Allogene Therapeutics and Equillium tied by winning 7 of the 14 factors compared between the two stocks.

How does Equillium compare to CorMedix?

Equillium (NASDAQ:EQ) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Equillium has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

CorMedix has a net margin of 45.25% compared to Equillium's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
CorMedix	45.25%	45.57%	24.76%

Equillium currently has a consensus target price of $7.57, suggesting a potential upside of 204.07%. CorMedix has a consensus target price of $14.86, suggesting a potential upside of 88.78%. Given Equillium's stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.82
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has higher revenue and earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.32	N/A
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69

27.0% of Equillium shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Equillium had 3 more articles in the media than CorMedix. MarketBeat recorded 6 mentions for Equillium and 3 mentions for CorMedix. Equillium's average media sentiment score of 1.34 beat CorMedix's score of 1.07 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Equillium and CorMedix tied by winning 8 of the 16 factors compared between the two stocks.

How does Equillium compare to CytomX Therapeutics?

Equillium (NASDAQ:EQ) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 204.07%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 273.46%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.82
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Equillium has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

27.0% of Equillium shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Equillium has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Equillium. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.32	N/A
CytomX Therapeutics	$76.20M	7.24	-$17.37M	-$0.41	N/A

In the previous week, Equillium had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Equillium and 4 mentions for CytomX Therapeutics. Equillium's average media sentiment score of 1.34 beat CytomX Therapeutics' score of 1.23 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats Equillium on 9 of the 15 factors compared between the two stocks.

How does Equillium compare to Neurogene?

Equillium (NASDAQ:EQ) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Neurogene's return on equity of -37.88% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Neurogene	N/A	-37.88%	-34.70%

Equillium presently has a consensus price target of $7.57, indicating a potential upside of 204.07%. Neurogene has a consensus price target of $84.83, indicating a potential upside of 143.08%. Given Equillium's higher possible upside, analysts clearly believe Equillium is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.82
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

27.0% of Equillium shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Equillium has higher earnings, but lower revenue than Neurogene. Equillium is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.32	N/A
Neurogene	$930K	592.92	-$90.35M	-$4.55	N/A

In the previous week, Equillium had 5 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Equillium and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.50 beat Equillium's score of 1.34 indicating that Neurogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Equillium	Positive
Neurogene	Positive

Equillium has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Summary

Equillium and Neurogene tied by winning 7 of the 14 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EQ vs. The Competition

Export

Metric	Equillium	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$170.08M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-7.78	21.11	27.00	23.71
Price / Sales	N/A	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	5.30	7.88	10.28	6.07
Net Income	-$22.40M	$23.81M	$3.60B	$331.99M
7 Day Performance	-3.86%	-3.82%	-1.29%	-0.61%
1 Month Performance	-15.59%	-2.61%	-0.38%	-1.98%
1 Year Performance	518.33%	32.79%	18.32%	13.67%

Equillium Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EQ Equillium	3.1598 of 5 stars	$2.49 -7.4%	$7.57 +204.1%	+578.5%	$170.08M	N/A	N/A	40	News Coverage Positive News Analyst Upgrade
TECX Tectonic Therapeutic	3.3002 of 5 stars	$32.80 +2.3%	$79.40 +142.1%	+36.3%	$618.94M	N/A	N/A	120
ALLO Allogene Therapeutics	2.6205 of 5 stars	$1.85 +4.5%	$8.52 +360.7%	+15.2%	$610.92M	$20K	N/A	310	Gap Down
CRMD CorMedix	2.9863 of 5 stars	$8.19 +5.3%	$14.86 +81.4%	-31.6%	$610.36M	$311.71M	4.12	30	Positive News
CTMX CytomX Therapeutics	2.4553 of 5 stars	$3.42 -2.8%	$12.10 +253.8%	+35.6%	$599.06M	$76.20M	N/A	170	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EQ) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equillium (EQ) Competitors

EQ vs. TECX, ALLO, CRMD, CTMX, and NGNE

How does Equillium compare to Tectonic Therapeutic?

Summary

How does Equillium compare to Allogene Therapeutics?

Summary

How does Equillium compare to CorMedix?

Summary

How does Equillium compare to CytomX Therapeutics?

Summary

How does Equillium compare to Neurogene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equillium (EQ) Competitors

EQ vs. TECX, ALLO, CRMD, CTMX, and NGNE

How does Equillium compare to Tectonic Therapeutic?

Is TECX or EQ more profitable?

Which has more risk & volatility, TECX or EQ?

Do analysts recommend TECX or EQ?

Which has stronger earnings and valuation, TECX or EQ?

Does the media prefer TECX or EQ?

Do institutionals & insiders believe in TECX or EQ?

Summary

How does Equillium compare to Allogene Therapeutics?

Is ALLO or EQ more profitable?

Do analysts rate ALLO or EQ?

Does the media refer more to ALLO or EQ?

Do institutionals and insiders hold more shares of ALLO or EQ?

Which has more volatility and risk, ALLO or EQ?

Which has stronger valuation & earnings, ALLO or EQ?

Summary

How does Equillium compare to CorMedix?

Which has more volatility & risk, EQ or CRMD?

Is EQ or CRMD more profitable?

Do analysts prefer EQ or CRMD?

Which has preferable earnings & valuation, EQ or CRMD?

Do insiders and institutionals hold more shares of EQ or CRMD?

Does the media favor EQ or CRMD?

Summary

How does Equillium compare to CytomX Therapeutics?

Do analysts prefer EQ or CTMX?

Is EQ or CTMX more profitable?

Do insiders & institutionals hold more shares of EQ or CTMX?

Which has more volatility and risk, EQ or CTMX?

Which has preferable valuation and earnings, EQ or CTMX?

Does the media prefer EQ or CTMX?

Summary

How does Equillium compare to Neurogene?

Is EQ or NGNE more profitable?

Do analysts prefer EQ or NGNE?

Do insiders and institutionals hold more shares of EQ or NGNE?

Which has stronger earnings & valuation, EQ or NGNE?

Does the media favor EQ or NGNE?

Which has more risk & volatility, EQ or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools